Mission
ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value. Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.
Staff Only
| Evidence Review Group Formation |
|
The Evidence Review Group (ERG) is an independent group brought together by ICER and composed of academic experts, patients, clinicians, epidemiologists, ethicists, and medical policy representatives of stakeholder groups including health plans and manufacturers. The purpose of the ERG is to guide and help interpret the entire appraisal process. Members of the ERG are first convened to function as a “scoping committee” for the appraisal. During this phase the key questions for the appraisal are outlined, including elements such as the appropriate comparator technologies, patient outcomes of interest, patient subpopulations for which clinical and cost-effectiveness may vary systematically, time horizon for outcomes, and key aspects of the existing data that must be taken into account during the appraisal. The ERG may be divided into sub-committees that advise the ICER appraisal team at the mid-point of the appraisal on the early findings and challenges encountered. At the final ERG meeting, members are asked to declare any interests in the technology or its comparator(s). The ERG meeting allows for in-depth deliberation on the findings of the ICER appraisal document and provides an opportunity for comment on the determination of the ICER integrated evidence rating. Although the ERG helps guide the final determination of the ICER Integrated Evidence Rating™, the final rating is ultimately a judgment made by ICER, and individual members of the ERG should not be viewed in any way as having endorsed this appraisal. |